Evaluation of the Efficacy of Intense Pulse Light Combined With Lipiflow in the Treatment of Meibomian Gland Dysfunction

Not Applicable

• Conditions: Meibomian Gland Dysfunction
• Interventions: Procedure: IPL/MGX; Procedure: IPL/Lipiflow

• Registration Number: NCT04633798
• Lead Sponsor: Aier School of Ophthalmology, Central South University

Brief Summary

To compare the effect of IPL combined with lipiflow and IPL combined with meibomian gland massage in treating meibomian gland dysfunction of different degrees ,focusing on effective rate, lasting time and changes of meibomian gland function and morphology.

Detailed Description

To divide all participants into two groups, group one treated with IPL combined with Lipiflow and group two treated with IPL combined with meibomian gland massage.The following parameters were recorded after treatment: the effective rate, lasting time and changes of meibomian gland function and morphology.All parameters were compared between the two groups.

Study Timeline

• Study First Submitted: 2020-05-20
• Status Verified: 2020-11
• Study First Submitted QC: 2020-11-16
• Last Update Submitted: 2020-11-16
• Study First Posted: 2020-11-18
• Last Update Posted: 2020-11-18
• Study Start: 2020-12-01
• Primary Completion: 2020-12-21
• Study Completion: 2020-12-21

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

• patients with meibomian gland dysfunction
• patients with ocular discomfort
• skin type:FitzpatricⅠ-Ⅳ

Exclusion Criteria

• patients with acute ocular inflammation
• eye surgery history in the last 12 months
• patients who have received IPL or Lipiflow in the last 12 months
• patients who wear contact lens in last one month

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
IPL/MGX	IPL/MGX	the group in which patients treated with IPL combined with meibomian gland massage
IPL/Lipiflow	IPL/Lipiflow	the group in which patients treated with IPL combined with lipiflow

Primary Outcome Measures

Name	Time	Method
ocular surface disease index(OSDI)	6 months	The OSDI is assessed on a scale of 0 to 100,with higher scores representing greater disability
meibomian gland expressibility score and meibum quality score	6 months	The score is on a scale of 0 to 6.The higher scores, the severity of the meibomian gland function(the highest score is 6 and the lowest score is 0)
meibomian gland dropout score	6 months	the higher scores, the severity of the meibomian gland morphology(The highest score is 6 and the lowest score is 0)
Breakup time	6 months	the shorter time, the poorer of the tear film stability